Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 8/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | STK4 | Q13043 | 1/20 | 0.37 |
| ▸ | STK3 | Q13188 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19533409 | 0.84 | AKT1 (0.39) | AKT1TRPA1IRAK4LIMK1ROCK2 | |
| SCHEMBL14649091 | 0.81 | TRPA1 (0.44) | AKT1TRPA1IRAK4CHEK1BRAF | |
| SCHEMBL10259826 | 0.81 | AKT1 (0.45) | AKT1TRPA1IRAK4LIMK1ROCK2 | |
| SCHEMBL19306619 | 0.79 | BRAF (0.41) | AKT1TRPA1IRAK4CHEK1BRAF | |
| SCHEMBL21620551 | 0.79 | CHEK1 (0.47) | AKT1TRPA1CHEK1BRAFTNNI3K | |
| SCHEMBL2537071 | 0.79 | CHEK1 (0.61) | AKT1TRPA1IRAK4LIMK1ROCK2 | |
| SCHEMBL20171693 | 0.79 | CHEK1 (0.47) | AKT1TRPA1IRAK4LIMK1ROCK2 | |
| SCHEMBL357993 | 0.79 | CHEK1 (0.61) | AKT1TRPA1IRAK4LIMK1ROCK2 | |
| SCHEMBL1804027 | 0.79 | AKT1 (0.44) | AKT1TRPA1IRAK4LIMK1ROCK2 | |
| SCHEMBL25528119 | 0.79 | AKT1 (0.41) | AKT1TRPA1IRAK4LIMK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| WO-2023102228-A1 | HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023020640-A1 | 7-SUBSTITUTED 7-DEAZAADENINE-CONTAINING 2',3'-CYCLIC DINUCLEOTIDES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2023-02-23 | — | — | WO | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2922596-B1 | HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES | NOVADRUG LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| WO-2017201187-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-3077395-B1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| WO-2017027645-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-9511070-B2 | Heterocyclyl carboxamides for treating viral diseases | NOVADRUG, LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| US-20150238489-A1 | HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES | NOVADRUG, LLC | 2015-08-27 | — | — | US | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2012080735-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | JAK3, JAK1, JAK2 | AKT1 1859/4885TRPA1 4008/4885IRAK4 29/4885 |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | AKT1 131/4885TRPA1 4815/4885IRAK4 648/4885 |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | AKT1 2136/4885TRPA1 1604/4885IRAK4 1827/4885 |
| US-20230285397-A1 | EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | AKT1 90/4885TRPA1 2035/4885IRAK4 1321/4885 |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TYMP, DPYD, TYMS | AKT1 1260/4885TRPA1 3557/4885IRAK4 4195/4885 |
| US-20150238489-A1 | HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES | SARS1, PYCARD, BRD1 | AKT1 4352/4885TRPA1 1091/4885IRAK4 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.